908 Devices Acquires NIRLAB AG to Strengthen Narcotics Detection Capabilities
核心洞察
908 Devices completed the acquisition of Swiss-based NIRLAB AG (搜索) for $15 million upfront, with up to $8 million in additional milestone payments over 20 months.
NIRLAB's AI-powered NIR spectroscopy platform enables handheld analysis of over 400 common drugs in seconds, with proven field performance of over one million analyses.
The acquisition expands 908 Devices' analytical portfolio and creates an end-to-end workflow solution for law enforcement agencies addressing the fentanyl and illicit drug crisis.
908 Devices Inc. (Nasdaq: MASS) has completed its acquisition of NIRLAB AG (搜索), a Swiss-based company specializing in AI-powered near-infrared spectroscopy for handheld chemical analysis of narcotics. The strategic acquisition strengthens 908 Devices' position in narcotics detection technology and expands its analytical portfolio for law enforcement applications.
Acquisition Details and Financial Terms
The purchase consideration includes an upfront payment of $15 million, consisting of $13 million in cash and $2 million of 908 Devices common stock. The purchase agreement also includes up to an additional $8 million in 908 Devices common stock upon the achievement of performance milestones over the next 20 months.
NIRLAB AG (搜索) was founded in 2021 as a spin-out of the University of Lausanne, a global leader in forensic science. The company is based in Switzerland and employs 15 people.
Technology Platform and Capabilities
The NIRLAB handheld device enables safe, point-and-click analysis of more than 400 common drugs, such as cocaine and methamphetamine, directly or through thin plastic bags and glass, delivering results in seconds to support real-time decision-making in the field. Beyond identification, the technology quantifies drug purity in complex mixtures and can analyze cannabis, including percentages of THC and CBD.
The platform has proven field performance with over one million analyses completed. It integrates an intuitive mobile app, seamless device connectivity, and a subscription model that delivers continuous updates and evolving capabilities through cloud-connected near-infrared spectroscopy.
Strategic Impact and Market Position
"We're thrilled to welcome the NIRLAB team to 908 Devices. Our combination creates a powerful end-to-end workflow advantage for our law enforcement customers," said Kevin J. Knopp, CEO and Co-founder of 908 Devices. "From fast, simple screening to trace-level analysis to detection of a broad range of substances, we offer a comprehensive solution for field-based chemical identification."
The acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcotics detection with NIRLAB's solution for fast, high-volume screening for everyday law enforcement patrol.
Company Background and Mission
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats.
"We are excited to join 908 Devices and bring our NIR technology to a global audience," said Florentin Coppey and Matteo Delbrueck, co-CEOs of NIRLAB AG (搜索). "Combining our proven technology platform with 908 Devices' market leadership, commercial infrastructure, and complementary product portfolio creates a powerful opportunity to better serve law enforcement agencies worldwide."